Proqr Therapeutics NV Schedule 13G passive stakes

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 6.33% in ProQR Therapeutics NV's ordinary shares.

Eli Lilly and Company has reported a significant beneficial ownership stake of 15.6% in ProQR Therapeutics N.V., holding 21,995,880 ordinary shares.

Several entities and an individual have updated their beneficial ownership filings for ProQR Therapeutics N.V. ordinary shares, collectively holding a significant stake.

Multiple Dutch investment entities and their portfolio manager have disclosed passive beneficial ownership stakes in ProQR Therapeutics N.V., with Privium Fund Management B.V. and Patrick Johan Hendrik Krol each holding 5.2%.

Adage Capital Management, L.P. and its principals have disclosed a 6.27% beneficial ownership stake in ProQR Therapeutics N.V. as of June 30, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 7.70% of ProQR Therapeutics N.V.'s Ordinary Shares as of March 31, 2025.

A group of Dutch investment entities and foundations, led by Adrianus van Herk, have disclosed a collective beneficial ownership of 10.9% in ProQR Therapeutics N.V., totaling 11,461,995 ordinary shares.

Adage Capital Management, L.P. and its principals have disclosed a 9.30% passive beneficial ownership stake in ProQR Therapeutics N.V. as of December 31, 2024.